Acticor Biotech SAS

EPA:ALACT.PA

0.38 (EUR) • At close September 16, 2024
Bedrijfsnaam Acticor Biotech SAS
Symbool ALACT.PA
Munteenheid EUR
Prijs 0.375
Beurswaarde 5,908,210
Dividendpercentage 0%
52-weken bereik 0.234 - 5.78
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gilles Avenard M.D.
Website https://acticor-biotech.com

An error occurred while fetching data.

Over Acticor Biotech SAS

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for

Vergelijkbare Aandelen

Affluent Medical SA logo

Affluent Medical SA

AFME.PA

1.88 EUR

GeNeuro SA logo

GeNeuro SA

GNRO.PA

0.065 EUR

Valbiotis SA logo

Valbiotis SA

ALVAL.PA

1.322 EUR

Poxel S.A. logo

Poxel S.A.

POXEL.PA

0.525 EUR

ABIONYX Pharma SA logo

ABIONYX Pharma SA

ABNX.PA

1.244 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)